Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2010 (2010), Article ID 539581, 11 pages
Review Article

The S100B/RAGE Axis in Alzheimer's Disease

1Department of Pharmaceutical Sciences, North Dakota State University, Dept. 2665, P.O. Box 6050, Fargo, ND 58108-6050, USA
2Department of Drug Discovery, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA

Received 4 March 2010; Accepted 6 May 2010

Academic Editor: Rosario Donato

Copyright © 2010 Estelle Leclerc et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Increasing evidence suggests that the small EF-hand calcium-binding protein S100B plays an important role in Alzheimer's disease. Among other evidences are the increased levels of both S100B and its receptor, the Receptor for Advanced Glycation Endproducts (RAGEs) in the AD diseased brain. The regulation of RAGE signaling by S100B is complex and probably involves other ligands including the amyloid beta peptide (A 𝛽 ), the Advanced Glycation Endproducts (AGEs), or transtheyretin. In this paper we discuss the current literature regarding the role of S100B/RAGE activation in Alzheimer's disease.